Afatinib-mediated EGFR inhibition was effective against all BTSCs tested; however, the degree of sensitivity was influenced by the status of common GBM molecular alterations, including EGFR mutations and PTEN inactivation (Figure 1A and Supplementary Table S1). Here, EGFR is linked to glioblastoma.